Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors

被引:9
作者
Baues, Christian [1 ,2 ,3 ,4 ,5 ]
Trommer-Nestler, Maike [1 ,2 ,3 ]
Jablonska, Karolina [1 ,2 ]
Broeckelmann, Paul J. [4 ,5 ,6 ]
Schlaak, Max [3 ,5 ,7 ]
von Bergwelt-Baildon, Michael [3 ,5 ,6 ]
Engert, Andreas [4 ,5 ,6 ]
Semrau, Robert [1 ,2 ,4 ,5 ]
Marnitz, Simone [1 ,2 ,4 ,5 ]
Theurich, Sebastian [3 ,5 ,6 ]
机构
[1] Univ Hosp Cologne, Dept Radiooncol, Cologne, Germany
[2] Univ Hosp Cologne, CyberKnife Ctr, Cologne, Germany
[3] Univ Hosp Cologne, Radioimmune Oncol Consortium RIO, Cologne, Germany
[4] Univ Hosp Cologne, German Hodgkin Study Grp, Cologne, Germany
[5] Univ Hosp Cologne, Ctr Integrated Oncol CIO Cologne, Cologne, Germany
[6] Univ Hosp Cologne, Dept Internal Med Hematol & Oncol 1, Cologne, Germany
[7] Univ Hosp Cologne, Dept Dermatol & Venerol, Cologne, Germany
关键词
abscopal effect; Hodgkin lymphoma; radio-immunotherapy; STEM-CELL TRANSPLANTATION; TUMOR-SPECIFIC IMMUNITY; RADIATION-THERAPY; SPONTANEOUS REGRESSION; BRENTUXIMAB VEDOTIN; SINGLE-ARM; PHASE-II; T-CELLS; HEPATOCELLULAR-CARCINOMA; ABSCOPAL REGRESSION;
D O I
10.2217/imt-2017-0002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Radiotherapy is an established local treatment in patients with various malignancies. Systemic responses following local irradiation have been described as abscopal effects. Modern cancer immunotherapy with immune checkpoint inhibitors has shown impressive response rates and prolongation of survival even in heavily pretreated patients with advanced solid malignancies and lymphomas. Radiotherapy has been shown to modulate immune response, and its application in the context of immune checkpoint inhibition has recently evolved into an active field of research. Prospective studies investigating combination treatment are currently ongoing and will answer questions as to the optimal schedule and radiation dosing. This short review focuses on the immunomodulatory role of radiotherapy and the use of immune checkpoint inhibition with a special focus on Hodgkin lymphoma.
引用
收藏
页码:423 / 433
页数:11
相关论文
共 131 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Allison JP, 2007, NOV FDN S 215 IMM TO, P92
  • [3] [Anonymous], BLOOD
  • [4] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [5] LYMPH-ANGIOGRAPHIC DEMONSTRATION OF ABSCOPAL EFFECT IN PATIENTS WITH MALIGNANT-LYMPHOMAS
    ANTONIADES, J
    BRADY, LW
    LIGHTFOOT, DA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 (1-2): : 141 - 147
  • [6] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059
  • [7] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [8] Baues C, 2016, STRAHLENTHER ONKOL, P1
  • [9] Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
    Behringer, Karolin
    Goergen, Helen
    Hitz, Felicitas
    Zijlstra, Josee M.
    Greil, Richard
    Markova, Jana
    Sasse, Stephanie
    Fuchs, Michael
    Topp, Max S.
    Soekler, Martin
    Mathas, Stephan
    Meissner, Julia
    Wilhelm, Martin
    Koch, Peter
    Lindemann, Hans-Walter
    Schalk, Enrico
    Semrau, Robert
    Kriz, Jan
    Vieler, Tom
    Bentz, Martin
    Lange, Elisabeth
    Mahlberg, Rolf
    Hassler, Andre
    Vogelhuber, Martin
    Hahn, Dennis
    Mezger, Joerg
    Krause, Stefan W.
    Skoetz, Nicole
    Boell, Boris
    von Tresckow, Bastian
    Diehl, Volker
    Hallek, Michael
    Borchmann, Peter
    Stein, Harald
    Eich, Hans
    Engert, Andreas
    [J]. LANCET, 2015, 385 (9976) : 1418 - 1427
  • [10] Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
    Boell, Boris
    Goergen, Helen
    Behringer, Karolin
    Broeckelmann, Paul J.
    Hitz, Felicitas
    Kerkhoff, Andrea
    Greil, Richard
    von Tresckow, Bastian
    Eichenauer, Dennis A.
    Buerkle, Carolin
    Borchmann, Sven
    Fuchs, Michael
    Diehl, Volker
    Engert, Andreas
    Borchmann, Peter
    [J]. BLOOD, 2016, 127 (18) : 2189 - 2192